GGrantIndex
← Leaderboards

Joel M. Gottesfeld

Scripps Research Institute

Google Scholar ↗PubMed ↗ORCID ↗
$21,130,203
Attributed
$23,281,185
Total exposure
13
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.2M · FY2005–19
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19

Funding mix

By agency

NIH$23,281,185 · 13

By mechanism

R01$16,341,904 · 8
U01$5,122,482 · 1
R21$1,804,031 · 3
P41$12,768 · 1

Top collaborators

Most similar at Scripps Research Institute

Same institution · by research overlap

Others in their field

Top investigators on “Gene Expression”

Research focus

Gene ExpressionCellsBaseProteinsGenesTranscription FactorToxic EffectMolecularCell LineGenetic TranscriptionResearch StudySmall MoleculeMouse ModelIntronsGeneticHistone Deacetylase InhibitorIn VivoLengthInheritedNeuronsCell ModelPyrrolesPharmaceutical PreparationsMessenger Rna

Grant awards (53)

Pathogenesis of age-related Fuchs Endothelial Corneal Dystrophy$504,968
R01 · FY2019 · EY
Application of RNA-targeting Cas9 to Fuchs' dystrophy$391,677
R01 · FY2019 · EY
Pathogenesis of age-related Fuchs Endothelial Corneal Dystrophy$504,968
R01 · FY2018 · EY
Mechanisms of Gene Silencing of Friedreich's Ataxia$421,094
R01 · FY2018 · NS · contact PI
Application of RNA-targeting Cas9 to Fuchs' dystrophy$391,679
R01 · FY2018 · EY
Pathogenesis of age-related Fuchs Endothelial Corneal Dystrophy$504,968
R01 · FY2017 · EY
Mechanisms of Gene Silencing of Friedreich's Ataxia$421,094
R01 · FY2017 · NS · contact PI
Pathogenesis of age-related Fuchs Endothelial Corneal Dystrophy$519,718
R01 · FY2016 · EY
Mechanisms of Gene Silencing of Friedreich's Ataxia$421,094
R01 · FY2016 · NS · contact PI
Transcription therapeutics for myotonic dystrophy type 1$436,200
R21 · FY2015 · NS · contact PI
Mechanisms of Gene Silencing of Friedreich's Ataxia$414,531
R01 · FY2015 · NS · contact PI
Transcription therapeutics for myotonic dystrophy type 1$480,950
R21 · FY2014 · NS · contact PI
Mechanisms of Gene Silencing of Friedreich's Ataxia$414,531
R01 · FY2014 · NS · contact PI
Novel Histone Deacetylase Inhibitors as Therapeutics for Huntington's Disease$511,096
U01 · FY2013 · NS · contact PI
Mechanisms of Gene Silencing in Friedreich's Ataxia$392,850
R01 · FY2013 · NS · contact PI
Novel Histone Deacetylase Inhibitors as Therapeutics for Huntington's Disease$1,600,018
U01 · FY2012 · NS · contact PI
Mechanisms of Gene Silencing in Friedreich's Ataxia$407,098
R01 · FY2012 · NS · contact PI
Novel Histone Deacetylase Inhibitors as Therapeutics for Huntington's Disease$20,250
U01 · FY2012 · NS · contact PI
Novel Histone Deacetylase Inhibitors as Therapeutics for Huntington's Disease$1,588,726
U01 · FY2011 · NS · contact PI
Mechanisms of Gene Silencing in Friedreich's Ataxia$407,098
R01 · FY2011 · NS · contact PI
Novel Histone Deacetylase Inhibitors as Therapeutics for Huntington's Disease$32,001
U01 · FY2011 · NS · contact PI
EFFECT OF HDAC INHIBITORS ON THE INTERACTION BETWEEN HDAC3 AND ITS PARTNERS$12,768
P41 · FY2011 · RR · contact PI
Novel Histone Deacetylase Inhibitors as Therapeutics for Huntington's Disease$1,370,391
U01 · FY2010 · NS · contact PI
Mechanisms of Gene Silencing in Friedreich's Ataxia$411,253
R01 · FY2010 · NS · contact PI
Small Molecular Therapeutics for Friedreich's Ataxia$409,870
R01 · FY2010 · NS · contact PI
Polyamide-Chl inhibition of cancer cell proliferation$527,155
R01 · FY2009 · CA · contact PI
Mechanisms of Gene Silencing in Friedreich's Ataxia$415,406
R01 · FY2009 · NS · contact PI
Small Molecular Therapeutics for Friedreich's Ataxia$414,010
R01 · FY2009 · NS · contact PI
Polyamide-Chl inhibition of cancer cell proliferation$533,302
R01 · FY2008 · CA · contact PI
Small Molecular Therapeutics for Friedreich's Ataxia$414,010
R01 · FY2008 · NS · contact PI
Polyamide-Chl inhibition of cancer cell proliferation$511,818
R01 · FY2007 · CA · contact PI
Small Molecular Therapeutics for Friedreich's Ataxia$406,145
R01 · FY2007 · NS · contact PI
Histone Deacetylase Inhibitors as Therapeutics for Friedreich's ataxia$243,687
R21 · FY2007 · NS · contact PI
Polyamide-Chl inhibition of cancer cell proliferation$514,779
R01 · FY2006 · CA · contact PI
Small Molecular Therapeutics for Friedreich's Ataxia$418,275
R01 · FY2006 · NS · contact PI
Histone Deacetylase Inhibitors as Therapeutics for Friedreich's ataxia$209,138
R21 · FY2006 · NS · contact PI
Polyamide-Chl inhibition of cancer cell proliferation$564,919
R01 · FY2005 · CA
Small molecule therapeutics for Friedreich's ataxia$217,028
R21 · FY2005 · NS
INHIBITION OF HIV GENE TRANSCRIPTION BY SMALL MOLECULES$504,387
R01 · FY2004 · GM
Specificity of Protein-DNA/RNA Interactions$296,320
R01 · FY2004 · GM
Small molecule therapeutics for Friedreich's ataxia$217,028
R21 · FY2004 · NS
INHIBITION OF HIV GENE TRANSCRIPTION BY SMALL MOLECULES$491,054
R01 · FY2003 · GM
Specificity of Protein-DNA/RNA Interactions$296,320
R01 · FY2003 · GM
INHIBITION OF HIV GENE TRANSCRIPTION BY SMALL MOLECULES$478,110
R01 · FY2002 · GM
SMALL MOLECULE REGULATION OF BREAST CANCER EXPRESSION$374,719
R01 · FY2002 · CA
Specificity of Protein-DNA/RNA Interactions$296,320
R01 · FY2002 · GM
INHIBITION OF HIV GENE TRANSCRIPTION BY SMALL MOLECULES$93,800
R01 · FY2002 · GM
INHIBITION OF HIV GENE TRANSCRIPTION BY SMALL MOLECULES$468,871
R01 · FY2001 · GM
SMALL MOLECULE REGULATION OF BREAST CANCER EXPRESSION$348,794
R01 · FY2001 · CA
Specificity of Protein-DNA/RNA Interactions$283,680
R01 · FY2001 · GM
INHIBITION OF HIV GENE TRANSCRIPTION BY SMALL MOLECULES$337,707
R01 · FY2000 · GM
SMALL MOLECULE REGULATION OF BREAST CANCER EXPRESSION$336,888
R01 · FY2000 · CA
SPECIFICITY OF DNA/RNA BINDING BY A ZINC FINGER PROTEIN$76,624
R01 · FY2000 · GM